Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Batm Advanced Communications Ld LSE:BVC London Ordinary Share IL0010849045 ORD ILS0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -0.46% 108.50 541,962 16:35:03
Bid Price Offer Price High Price Low Price Open Price
107.50 108.50 112.50 107.50 112.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 93.75 0.95 0.07 1,647.6 481
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:58 O 50,000 108.50 GBX

Batm Advanced Communicat... (BVC) Latest News

More Batm Advanced Communicat... News
Batm Advanced Communicat... Investors    Batm Advanced Communicat... Takeover Rumours

Batm Advanced Communicat... (BVC) Discussions and Chat

Batm Advanced Communicat... Forums and Chat

Date Time Title Posts
20/1/202122:13Batm Advanced - A New Beginning18,030
18/7/202013:52BATM * BATM * BATM * BATM ******BUNG A ROCKET IN YER PORTFILIOS47
12/6/202016:27BVC over-ramped and over-valued!120
15/4/202009:44BATM - Broadband bright future22,489
03/2/202008:05Coronavirus Investment - BATM2

Add a New Thread

Batm Advanced Communicat... (BVC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-20 17:18:48108.5050,00054,250.00O
2021-01-20 17:07:58108.505,0005,425.00O
2021-01-20 16:37:19108.501,3771,494.05AT
2021-01-20 16:35:03108.5036,30039,385.50UT
2021-01-20 16:29:54107.501010.75AT
View all Batm Advanced Communicat... trades in real-time

Batm Advanced Communicat... (BVC) Top Chat Posts

DateSubject
20/1/2021
08:20
Batm Advanced Communicat... Daily Update: Batm Advanced Communications Ld is listed in the Technology Hardware & Equipment sector of the London Stock Exchange with ticker BVC. The last closing price for Batm Advanced Communicat... was 109p.
Batm Advanced Communications Ld has a 4 week average price of 90.60p and a 12 week average price of 78.40p.
The 1 year high share price is 150.50p while the 1 year low share price is currently 30p.
There are currently 443,543,901 shares in issue and the average daily traded volume is 683,454 shares. The market capitalisation of Batm Advanced Communications Ld is £481,245,132.59.
15/1/2021
18:30
paulisi: Thanks for the link - Zvi needs to make this common knowledge. Share price will jump when word gets out
12/1/2021
15:26
fse: I think the sale will go through as planned as there are penalty clauses if it does not so its fair to say its all but fait accomplis. I thought they would use NGSoft services more in their own arena but honestly they appear subsidiary to their needs so they might as well let it go. The price was a surprise as its a decent chunk of cash. We did receive an update on the state of business with this comment "BATM is focused on core areas of activity, underpinned by the Group's portfolio of intellectual property, that it expects will offer transformational growth opportunities in both its Networking & Cyber and Bio-Medical divisions. In particular, in 2020, the Group achieved fundamental milestones in progressing the development of its network function virtualisation ("NFV") activities, including a successful proof-of-concept of its NFVTime solution with Vodafone and securing its first tier 1 customer with a multi-year licensing agreement. In medical diagnostics, the Bio-Medical division rapidly produced multiple solutions in response to the COVID-19 outbreak that are experiencing substantial demand as the global pandemic continues." >JD..... yes I do consider the company currently undervalued. Fair trading range IMO would be in the 120p range up to 160P. I topped up when the share price dipped below 100p. I rate them a BUY at these levels. Its good news for shareholders.
12/1/2021
08:56
wizzkid211: According to the company: "By 2020 the group has achieved key milestones in the development progress of its virtual network (NFV) operations, including successful completion of feasibility trials of its NFV solution with Vodafone and has secured a multi-year license agreement with First Tire-1 customer in the field. "Diagnostics, the BioMed division has rapidly developed a large number of solutions in response to the eruption of the corona, which are in great demand and increase as the epidemic continues." "We treat viruses and other pathogens as a matter of routine, and as soon as we saw the corona virus spread we began to develop a series of diagnostic components needed to deal with the epidemic," describes Dr. Zvi Marom, co-founder and CEO of Batm. BATM has led to a 100% increase in its share price this year.
12/1/2021
07:02
wizzkid211: BATM Advanced Communications Ld BATM enters option agreement to sell NGSoft January 12 2021 - 02:00AM UK Regulatory (RNS & others) Alert Print Share On Facebook TIDMBVC RNS Number : 3160L BATM Advanced Communications Ld 12 January 2021 LEI: 213800FLQUB9J289RU66 12 January 2021 BATM Advanced Communications Limited ("BATM" or "the Group") BATM enters option agreement to sell NGSoft for c. $33m Disposal of legacy software services subsidiary to generate funds for acceleration of core activities BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has entered into an option agreement (the "Option Agreement") to sell NG Soft Ltd. ("NGSoft"), a subsidiary of the Group, for NIS 105.1m (approximately $33m) in cash to Aztek Technologies (1984) Ltd., a provider of ICT cloud services in Israel and a portfolio company of SKY Fund (the "Buyer"). Background to the transaction BATM is focused on core areas of activity, underpinned by the Group's portfolio of intellectual property, that it expects will offer transformational growth opportunities in both its Networking & Cyber and Bio-Medical divisions. In particular, in 2020, the Group achieved fundamental milestones in progressing the development of its network function virtualisation ("NFV") activities, including a successful proof-of-concept of its NFVTime solution with Vodafone and securing its first tier 1 customer with a multi-year licensing agreement. In medical diagnostics, the Bio-Medical division rapidly produced multiple solutions in response to the COVID-19 outbreak that are experiencing substantial demand as the global pandemic continues. As previously stated, BATM continuously seeks opportunities to unlock shareholder value from Group subsidiaries that are considered non-core to the future of the Group. NGSoft is a software and digital services company that provides creative digital and technology solutions. Its development activities do not include any of the Group's NFV or cyber solutions. Accordingly, the Board believes that it would be in the best interests of BATM and of all shareholders to generate value from the sale of NGSoft and invest the proceeds to accelerate the Group's core activities in accordance with its strategic plan. Terms of the transaction Under the terms of the Option Agreement, BATM has the option, but not obligation, to sell the entire issued share capital of NGSoft for a total cash consideration of NIS 105.1m (c. $33m), of which the Group would receive a total of NIS 93.7m (c. $29m). The Group's consideration includes a NIS 15.5m loan repayment from NGSoft and a NIS 2.1m dividend payment, both to be received upon the exercise of the option. Certain employees of NGSoft would receive the balance of NIS 11.4m through cash out of their employee options and rights on completion. In the event that the option is exercised by BATM, a share purchase agreement would be entered into - the final form of which has been agreed with the signatory pages being held in escrow by a trustee who would be required to release them upon being served with a notice of exercise of the option. The Buyer only has the right to terminate the agreement in the event of a material adverse change in the trading of NGSoft. The Group's option is exercisable up to and including 1 March 2021, which, in accordance with the terms of the Option Agreement, can be extended by the Group to 17 May 2021 under certain predefined circumstances. If the Group does not exercise its option, it will be required to pay the Buyer a consideration of up to NIS 7.9m in cash. The Group will update the market in due course. Enquiries:
04/1/2021
16:03
fse: Heres a slightly better translation from Hebrew from Wizz post above. Good spot. Looks like he is in the running for another business award. Of interest to shareholders is the comment that they don't need the money at the moment although he does not rule out a float on NASDAQ probably split off Telco. I cant see any reason for listing the medical side as its an amalgamation of several divisions that operate autonomously albeit in related fields. BATM founder and CEO, Dr. Zvi Marom, who made headlines this year with the corona tests he developed, reveals in an interview with BizPortal's People of the Year project that the company does not rule out a spin-off on NASDAQ and warns: "We treat viruses and other pathogens as a matter of routine, and as soon as we saw the corona virus spread we began to develop a range of diagnostic components needed to deal with the epidemic" - describes Dr. Zvi Marom, co-founder and CEO of Batm + 0.07%, how the company identified in time A real opportunity that has largely led to a more than 100% increase in its share price this year.Marom is one of BizPortal's system choices in BizPortal's People of the Year project for 2020, in which surfers will vote this week. Watch the full interview: "We did not go to Nasdaq because we do not need money at the moment," Marom explains why the company is not applying for an IPO on Wall Street. "At the moment, our shareholders are satisfied. It may be that in the future, if we spin parts of the company, we will also go to Nasdaq, During the interview, Marom says that the business environment in Israel has improved, but claims that "at the same time as exits, we should try to build strong local companies. "Unfortunately, most of the large manufacturing companies in Israel are foreign-owned, and it is dangerous because tomorrow morning an unnamed president of a company may decide to move the company to another location." Marom also warns against the escape of productive activity from Israel. "There is a double problem: both the size of the Israeli market, which must be export-oriented, and the government, which does not place any emphasis on the manufacturing sector." Marom noted that the corona kits developed by BATM also identify the British corona mutation, and will be able to identify the South African one and other mutations that may emerge in the future through various adjustments. "You could say in retrospect that we are reaping the rewards of a job we started a decade ago," says Marom, according to which the field of infectious diseases will continue to grow since "the corona goes nowhere - with and without the vaccine." In addition, Marom refers to BATM activities in the field of networking and cyber, as part of which a deal was signed with the giant Vodafone this year and the company enjoyed an increase in demand for wide network traffic due to moving from work in some workplaces and multimedia consumption during closures. Alongside these, Marom recounts how he rolled into the field, about his enjoyment of being involved in the development processes at BATM, about the many historical books he reads at home, about the friends from the world of culture and literature and the hobbies he cultivates in his spare time.
10/12/2020
09:39
owenski: $0.5 to $1.5m for an order at unknown margin on a near 400m M.cap company was never going to move the share price. Good to see their tech in a new vertical, but it doesn't exactly look like a fast moving sales item to me either. Share price has been weak for some time, probably in part because the heat has gone out of any rises connected with Covid. Whether 80p provides a share price floor time will tell, but the valuation here aint cheap either.
02/12/2020
13:04
owenski: The share price was 45p until mid April In mid April they announced a ventilator contract and the share price took off eventually reaching 150p by mid August I'd suggest that the share price got overheated in a short time frame on the back of a Covid related announcement. Testing is a crowded market place and come vaccine rollout, the market is forward looking to other areas now and not Covid testing. I also don't see ventilators as a growth area. Bit of a sobering thought, if this starts deflating back to the 40's, not saying it will, but that's where it came from pre-Covid contract news. I picked up on the chart signals mid September that this was going to correct downwards. Anyways, I'm in no rush to buy. IMO
02/12/2020
11:25
owenski: As said before the chart has looked weak for some time, for the record, I like the business. "owenski - 29 Sep 2020 - 07:56:47 - 17618 of 17783 Odd share price action here considering the supposed good news flow. Looks like it's setting up to go of a cliff." As said before, the share price has looked weak here for some time, maybe it got a bit overvalued??"
09/11/2020
21:53
owenski: "owenski - 29 Sep 2020 - 07:56:47 - 17618 of 17783 Odd share price action here considering the supposed good news flow. Looks like it's setting up to go of a cliff." As said before, the share price has looked weak here for some time, maybe it got a bit overvalued??
01/9/2020
20:46
deltaham: Here's the impressive article: Profiting from 5G BATM Advanced Communications (BVC:135p), a provider of medical laboratory systems, diagnostic kits, cyber security and network solutions, has made an incredibly important announcement since I covered the interim results (‘In search of value opportunities’, 17 August 2020). It’s one that has prompted me to upgrade my run profits stance on the shares to an outright buy recommendation. That’s because the company has signed up its first tier 1 customer for the group’s NFVTime virtual networking solution. The cutting-edge technology enables network carriers to remotely deploy their own virtualised software-based networks and operates on both Arm-based and Intel-based architectures. The customer is a leading Asian telecommunications provider that serves enterprise and wholesale customers in more than 160 countries and 3,000 cities across the Americas, Asia, Europe, Middle East and Africa. It has licenced BATM’s NFVTime operating system for a minimum of three years. Analysts at house broker Shore Capital estimate that the market for virtualisation services “stretches into tens of billions of dollars” and revenue from the new tier 1 customer has “potential to scale into a multi-million dollar, recurring base over the next five years.” It’s incredibly high margin, too, with gross margin “building up from the 80 per cent range”. That’s a significantly higher margin than BATM makes on its traditional carrier Ethernet products. Moreover, expect further contract wins to be announced as other large tier 1 customers adopt the technology, given that NFV is a critical element in leveraging the benefits offered by 5G and Internet of Things. This highlights the potential for BATM’s revenue and cash flow to scale up rapidly. Not surprisingly, investors have reacted positively to the news. BATM’s share price rallied 15 per cent following the contract win taking the total return on the holding to 650 per cent since I included the shares in my 2017 Bargain Shares portfolio. I now feel that the earnings upgrade cycle I previously highlighted is poised to accelerate. I also feel that BATM is a US$1bn market capitalisation company in the making, implying a new target price of 171p. A cash profit multiple of 50 times to enterprise valuation may not seem a bargain, but given the high margin nature of BATM’s revenue streams, and the way it is monetising its patent protected IP, that multiple could drop like a stone if further NFV contracts are secured. From a technical perspective, a chart break-out above the 19-year high of 150p would confirm the next up-leg in the share price is underway. On a bid-offer spread of 134.5p to 135p, I rate BATM’s shares a buy.
Batm Advanced Communicat... share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
BVC
Batm Advan..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210121 03:18:26